12:00 AM
Feb 17, 2014
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AVI-7288: Phase I data

A double-blind, placebo-controlled, U.S. Phase I trial in 40 healthy volunteers showed that once-daily 1, 4, 8, 12 and 16 mg/kg doses of IV AVI-7288 for 14 days were well tolerated with no serious or clinically significant adverse events...

Read the full 173 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >